| Gaucher Disease, Type 1
Elelyso vs Zavesca
Side-by-side clinical, coverage, and cost comparison for gaucher disease, type 1.Deep comparison between: Elelyso vs Zavesca with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZavesca has a higher rate of injection site reactions vs Elelyso based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zavesca but not Elelyso, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Elelyso
Zavesca
At A Glance
IV infusion
Every 2 weeks
Enzyme replacement therapy (glucocerebrosidase)
Oral
Three times daily
Glucosylceramide synthase inhibitor
Indications
- Gaucher Disease, Type 1
- Gaucher Disease, Type 1
Dosing
Gaucher Disease, Type 1 (treatment-naive) 60 units/kg IV every other week as a 60- to 120-minute intravenous infusion.
Gaucher Disease, Type 1 (switching from imiglucerase) Initiate at the same units/kg imiglucerase dosage via IV infusion (60- to 120-minute) every other week; adjust dosage based on achievement and maintenance of therapeutic goals.
Gaucher Disease, Type 1 100 mg orally three times daily at regular intervals; may reduce to 100 mg once or twice daily for tremor or diarrhea; initiate at 100 mg twice daily for mild renal impairment (CrCl 50-70 mL/min/1.73 m2), 100 mg once daily for moderate impairment (CrCl 30-50 mL/min/1.73 m2); not recommended for severe renal impairment.
Contraindications
—
—
Adverse Reactions
Most common (>=5%), treatment-naive adults Headache, arthralgia, fatigue, nausea, dizziness, abdominal pain, pruritus, flushing, vomiting, urticaria
Most common (>=10%), switched from imiglucerase Arthralgia, headache, pain in extremity
Postmarketing Vomiting, diarrhea, fatigue, anaphylaxis, type III immune mediated fixed drug eruption, back pain
Most common (>=5%) Diarrhea, flatulence, abdominal pain, nausea, weight decrease, headache, tremor, thrombocytopenia
Serious Peripheral neuropathy
Pharmacology
Enzyme replacement therapy; taliglucerase alfa is a recombinant analog of human lysosomal glucocerebrosidase that catalyzes the hydrolysis of glucocerebroside to glucose and ceramide, reducing substrate accumulation in macrophages of patients with Gaucher disease.
Miglustat is a competitive and reversible inhibitor of glucosylceramide synthase, reducing glycosphingolipid biosynthesis so that the residual activity of deficient glucocerebrosidase can more effectively degrade glucosylceramide substrate (substrate reduction therapy).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Elelyso
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Zavesca
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Elelyso
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Zavesca
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Elelyso
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Zavesca
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Gaucher Disease - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Gaucher Disease - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ElelysoView full Elelyso profile
ZavescaView full Zavesca profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.